We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medilink | LSE:MEDI | London | Ordinary Share | JE00B3FFC377 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.30 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMEDI
RNS Number : 3657F
Medilink-Global UK Limited
27 July 2016
27 July 2016
MediLink-Global UK Limited
("MediLink" or "the Company")
Intention to seek cancellation from trading on AIM
The Board of MediLink announces that it has decided to seek shareholder approval for the cancellation of the Company's ordinary shares from trading on AIM ("Cancellation"). The Directors consider that the costs associated with having its shares admitted to trading on AIM ("Admission") are not commensurate with the associated benefits of Admission.
The Company intends to convene a general meeting shortly, at which it will propose a resolution to approve the Cancellation in accordance with Rule 41 of the AIM Rules for Companies. For Cancellation to become effective, the Company will require not less than 75% of the votes cast by shareholders on the resolution to be in favour of approving the cancellation at the general meeting. A circular setting out, inter alia, further details of the rationale for seeking Cancellation, as well as proposed arrangements for trading in the Company's ordinary shares post cancellation, along with a notice of general meeting, will be prepared by the Company and posted to shareholders in due course.
The information contained within this announcement is deemed by the Directors of the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").
Further announcements will be made as appropriate.
Enquiries:
Hot Features
Premium
MediLink-Global UK Limited Allenby Capital Limited
(Nominated Adviser and
Broker)
Shia Kok Fat, Chief Nick Athanas
Executive Officer
Tel: 00 603 2296 3028 James Reeve
www.medilink-global.com Tel: +44(0)20 3328 5656
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUQAMUPQUMM
(END) Dow Jones Newswires
July 27, 2016 04:00 ET (08:00 GMT)
1 Year Medilink Chart |
1 Month Medilink Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
